UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 9, 2014
Date of Report (Date of Earliest Event Reported)
ALLERGAN, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 1-10269 | 95-1622442 | ||
(State of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
2525 Dupont Drive
Irvine, California 92612
(Address of Principal Executive Offices) (Zip Code)
(714) 246-4500
(Registrants Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On October 9, 2014, Allergan, Inc. issued a press release providing an update on earnings per share and sales expectations. A copy of the press release is furnished as Exhibit 99.1 hereto.
Item 8.01. Other Events
The disclosure under Item 2.02 is incorporated herein by reference
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 | Press Release dated October 9, 2014; Allergan Provides Update on Earnings Per Share and Sales Expectations |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALLERGAN, INC. | ||||||
Date: October 9, 2014 | ||||||
By: /s/ Matthew J. Maletta | ||||||
Name: | Matthew J. Maletta | |||||
Title: | Vice President, | |||||
Associate General Counsel and Secretary |
Exhibit Index
Exhibit |
Description of Exhibit | |
99.1 | Press Release dated October 9, 2014; Allergan Provides Update on Earnings Per Share and Sales Expectations |